


7th EBF Young Scientist Symposium



Reconnecting after Quarantine

10-11 June 2021

7th YSS - agenda

10 June 2021

- 11:30 13:00 Welcome at local sites - local site program as appropriate**
- 12:45 13:00 Coming online and start of the meeting for all**
- 13:00 13:10 Welcome**
Philip Timmerman
- 13:10 14:30 Session 1: Achieving better sensitivity and selectivity**
Chair/Moderator/Questions: Connor/Mathias/Salvatore
- 13:10 13:30 Steven Schoemaker - PRA-HS
Chiral derivatization for enhancing sensitivity and speed of the LC-MS/MS determination of the enantiomers of ibuprofen.
- 13:30 13:50 Claire Szuster - LGC
The diastereomer double-peak dilemma
- 13:50 14:10 Marco Cirrincione - University of Bologna
Enantiomeric separation of chiral synthetic opioids and metabolites in DBS by UHPLC-HRMS
- 14:10 14:30 Rosie Penford - GlaxoSmithKline
The identification and development of a fit for purpose biomarker assay using the MSD platform
- 14:45 15:15 Parallel Session 2**
Training Course: the basics of ADA in 30 minutes
presenter: Salvatore Calogero, on behalf of the EBF
- 14:45 15:15 Parallel Session 3**
Training Course: the basics of LC-MS in 30 minutes
presenter: Terrence Hetzel/Connor Walker, on behalf of the EBF
- 15:30 18:00 Session 4: Miniaturisation and automation**
Chair/Moderator/Questions: Michele/Ian/Muriel
- 15:30 15:50 Liesl Heughebaert - University of Ghent
Near-infrared-based hematocrit prediction of dried blood spots: an in-depth evaluation
- 15:50 16:10 Camilla Marasca - University of Bologna
Haematic volumetric microsampling for TDM of patients under treatment with lurasidone
- 16:10 16:30 Bryan van den Broek - Sanquin
Measuring antibodies in capillary blood: improvements by moving from dried blood spot to haematocrit independent micro-sampling
- 16:30 16:40 short break
- 16:40 17:00 George Walters - LGC
Automation vs Analyst: The Future of Bioanalysis
- 17:00 17:20 Sigrid Deprez - University of Ghent
Fully Automated Dried Blood Spot-Based Therapeutic Drug Monitoring of Immunosuppressants
- 17:20 17:40 John Smeraglia - UCB Pharma
Role of automation in maximizing portfolio value – the future is now
- 17:40 18:00 Scott Summerfield - GlaxoSmithKline
Transitioning to an 'automation-first' culture in Bioanalysis – our learnings from the last 3 year
- 18:00 End of Day 1 Q&A**

11 June 2021

09:45 Coming online

- 10:00 11:20 Science Café: "How has Covid-19 changed our future? "**
This year, the YSS-OC wants to engage you how Covid-19 impacted our (professional) careers, i.e. things we lost, for good or for bad – things we gained, wanted or unwanted, things we learned about ourselves and our industry. The YSS has prepared a panel discussion for all of you to contribute
- 11:30 12:10 Interactive poster viewing session (5-min poster pitch - posters 1 to 7)**
Chair/Moderator/Questions: Mathias/Robin
- 12:10 12:40 Lunch break**
- 12:50 13:30 Interactive poster viewing session (5-min poster pitch - posters 8 to 14)**
Chair/Moderator/Questions: Mathias/Robin
- 13:30 14:10 Was the 6th YSS' sustainability theme "sustainable"?**
13:30 13:50 Katja Zeiser - Nuvisan
Re-Validation concept for an optimized use of resources – what have we achieved?
13:50 14:10 5-min pitches of "what are WE doing on sustainability?"
Connor Walker (Arcinova – A Quotient Sciences Business), Adam Williams (AstraZeneca), Salvatore Calogero (F. Hoffmann – La Roche) and Ian Dawson (Covance)
- 14:10 14:40 Plenary Feedback from (local or e-) Science Café round tables**
- 15:00 16:20 Session 5: Novel approaches to ADA/complex assays – how did you overcome them?**
Chair/Moderator/Questions: Salvatore/Laura/Tessa
- 15:00 15:20 Hanna Leins - Nuvisan (awaiting approval to release)
One for all – development of a generic ADA assay on the Gyrolab Platform
- 15:20 15:40 Christina Aniol-Nielsen - NovoNordisk (awaiting approval to release)
Calibration-Free Concentration Analysis for Quantification of Anti-Drug Specific Antibodies in Positive Control Antibodies and in Clinical Samples
- 15:40 16:00 Eugenia Opolka-Hoffmann - F. Hoffmann La Roche (not reale)
The impact of drug/ADA immune complex properties on drug clearance: an *in vivo* study and the underlying bioanalytical method
- 16:00 16:20 Jayshee Maher - LGC
AlphaLISA – An alternative platform for immunogenicity assays?
- 16:40 18:20 Session 6: Biomarkers and CoU: an uphill journey for young scientists?**
Chair/Moderator/Questions: Tessa/Adam/Terence
- 16:40 16:50 Philip Timmerman - EBF
Introduction to the session & Background of EBF in relation to Biomarker assay validation
- 16:50 17:10 Kyra Cowan - on behalf of the EBF
Context of Use *versus* the BMV - why the discussion?
- 17:10 17:30 Léa Costes - Sanquin
Biomarker assays and context of use: two stories, one success
- 17:30 17:50 Michele Protti - University of Bologna
Pathology biomarkers in animal models of amyotrophic lateral sclerosis: microsampling-based analytical investigation
- 17:50 18:20 Panel discussion: CoU - an uphill journey for young scientists?
- 18:20 **Closing Remarks and Adjourn**

Meeting Organisation: Robin Wördenweber (A&M-Labor), Adam Williams (AstraZeneca), Connor Walker (Arcinova – A Quotient Sciences Business), Muriel Smet (Sanofi), Laura Schlicksupp (AbbVie), Mathias Salger (Nuvisan), Michele Protti (University of Bologna), Coral Munday (LGC), Jessica McGregor (ABS Labs), Tessa McDonald (Intertek - Manchester), Camilla Marasca (University of Bologna), Terence Hetzel (Bayer), Cara Gunning (Charles River), Liesl Heughebaert (Ghent University), Ian Dawson (Covance) and Salvatore Calogero (F. Hoffmann – La Roche).

Meeting management: Philip Timmerman (EBF)

7th YSS Patrons: Arcinova, Covance, Merck KGaA, Charles River, Phamidex, PRA-HS, Abbvie and Boehringer-Ingelheim